Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

Triple combination therapy to improve blood pressure control: experience with olmesartan-amlodipine-hydrochlorothiazide therapy.

Tocci G, Paneni F, Passerini J, Volpe M.

Expert Opin Pharmacother. 2012 Dec;13(18):2687-97. doi: 10.1517/14656566.2012.745510. Epub 2012 Nov 21. Review.

PMID:
23170911
2.

Olmesartan/amlodipine: a review of its use in the management of hypertension.

Kreutz R.

Vasc Health Risk Manag. 2011;7:183-92. doi: 10.2147/VHRM.S16852. Epub 2011 Mar 29. Review.

3.
4.

Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension.

Kereiakes DJ, Chrysant SG, Izzo JL Jr, Littlejohn T 3rd, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R.

J Clin Hypertens (Greenwich). 2012 Mar;14(3):149-57. doi: 10.1111/j.1751-7176.2011.00588.x. Epub 2012 Jan 24.

5.

ARB-based single-pill platform to guide a practical therapeutic approach to hypertensive patients.

Volpe M, de la Sierra A, Kreutz R, Laurent S, Manolis AJ.

High Blood Press Cardiovasc Prev. 2014 Jun;21(2):137-47. doi: 10.1007/s40292-014-0043-6. Epub 2014 Feb 15. Erratum in: High Blood Press Cardiovasc Prev. 2014 Jun;21(2):149-50.

PMID:
24532183
6.

Long-term efficacy of a combination of amlodipine and olmesartan medoxomil ± hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a substudy of the COACH trial.

Oparil S, Chrysant SG, Melino M, Lee J, Karki S, Heyrman R.

J Hum Hypertens. 2010 Dec;24(12):831-8. doi: 10.1038/jhh.2010.16. Epub 2010 Mar 4.

7.
8.

A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide.

Weir MR, Hsueh WA, Nesbitt SD, Littlejohn TJ 3rd, Graff A, Shojaee A, Waverczak WF, Qian C, Jones CJ, Neutel JM.

J Clin Hypertens (Greenwich). 2011 Jun;13(6):404-12. doi: 10.1111/j.1751-7176.2011.00437.x. Epub 2011 Feb 5.

9.

Safety and effectiveness of a fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide in clinical practice.

Bramlage P, Fronk EM, Wolf WP, Smolnik R, Sutton G, Schmieder RE.

Vasc Health Risk Manag. 2014 Dec 17;11:1-8. doi: 10.2147/VHRM.S75380. eCollection 2015.

10.

Amlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertension.

Chrysant SG.

Expert Rev Cardiovasc Ther. 2009 Aug;7(8):887-95. doi: 10.1586/erc.09.85.

PMID:
19673666
12.

Olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide triple combination for hypertension.

Ram CV.

Expert Rev Cardiovasc Ther. 2011 Jan;9(1):9-19. doi: 10.1586/erc.10.163. Review.

PMID:
21166525
13.

Olmesartan medoxomil/amlodipine/hydrochlorothiazide: fixed-dose combination in hypertension.

Deeks ED.

Drugs. 2011 Jan 22;71(2):209-20. doi: 10.2165/11206770-000000000-00000. Review.

PMID:
21275446
14.

Olmesartan medoxomil-based antihypertensive therapy evaluated by ambulatory blood pressure monitoring: efficacy in high-risk patient subgroups.

Chrysant SG, Germino FW, Neutel JM.

Am J Cardiovasc Drugs. 2012 Dec 1;12(6):375-89. doi: 10.2165/11636080-000000000-00000. Review.

PMID:
23116225
15.
17.

Combination therapy for hypertension: focus on high-dose olmesartan medoxomil (40 mg) plus hydrochlorothiazide.

Rump LC, Sellin L.

Expert Opin Pharmacother. 2010 Sep;11(13):2231-42. doi: 10.1517/14656566.2010.510834. Review.

PMID:
20707758
18.

Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.

da Silva PM.

Clin Drug Investig. 2010;30(9):625-41. doi: 10.2165/11538440-000000000-00000. Review.

PMID:
20626210
19.

Fixed-combination therapy to improve blood pressure control: experience with olmesartan-based therapy.

Tocci G, Volpe M.

Expert Rev Cardiovasc Ther. 2011 Jul;9(7):829-40. doi: 10.1586/erc.11.59. Review.

PMID:
21809963
20.

Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic.

Volpe M, Tocci G.

Vasc Health Risk Manag. 2012;8:371-80. doi: 10.2147/VHRM.S28359. Epub 2012 Jun 11. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk